A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

In conclusion, these results support anagrelide administration to high-risk Japanese ET patients using individualized dosing strategies defined in instructions previously approved in Europe and the USA. PMID: 30121892 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30121892?dopt=Abstract

Source: International Journal of Hematology - August 18, 2018 Category: Hematology Authors: Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, Achenbach H, Wu J, Nakaseko C Tags: Int J Hematol Source Type: research